Your browser doesn't support javascript.
loading
Endoscopic dilatation improves long-term dysphagia following head and neck cancer therapies: a randomized control trial.
Wu, P I; Szczesniak, M M; Maclean, J; Graham, P H; Quon, H; Choo, L; Cook, I J.
Afiliação
  • Wu PI; Department of Gastroenterology and Hepatology, St George Hospital, Sydney, NSW, Australia.
  • Szczesniak MM; Speech Pathology Department, St George Hospital, Sydney, NSW, Australia.
  • Maclean J; Department of Gastroenterology and Hepatology, St George Hospital, Sydney, NSW, Australia.
  • Graham PH; Speech Pathology Department, St George Hospital, Sydney, NSW, Australia.
  • Quon H; Speech Pathology Department, St George Hospital, Sydney, NSW, Australia.
  • Choo L; St George Clinical School, University of New South Wales, Sydney, NSW, Australia.
  • Cook IJ; Department of Radiation Oncology, Cancer Care Centre, St George Hospital, Sydney, NSW, Australia.
Dis Esophagus ; 32(6)2019 Jun 01.
Article em En | MEDLINE | ID: mdl-30462194
Long-term pharyngeal dysphagia is a common complication following head and neck cancer (HNC) therapies. High-level evidence for pharyngoesophageal junction (POJ) dilatation as a treatment in this population is lacking. We aimed to evaluate the safety and efficacy of POJ dilatation in dysphagic HNC survivors. This single-center, single-blind, placebo-controlled trial (St George Hospital, Sydney, Australia) randomly assigned (1:1) HNC survivors with long-term dysphagia (≥12 months postcompleted HNC therapies) to receive either graded endoscopic dilatations or sham dilatation (placebo). Patients were blinded to intervention types. Two strata were used for permuted randomization: (1) HNC therapies (total laryngectomy vs. chemoradiation alone); (2) Prior POJ dilatation (nil vs. previous dilatation). The primary endpoint was a short-term clinical response in swallowing function (3 months), defined as (1) a decrease in Sydney Swallow Questionnaire score by ≥200 or a score ≤ ULN; and (2) satisfactory global clinical assessment. The secondary endpoints were dysphagia relapse and serious adverse events. This trial is registered with the Australian New Zealand Clinical Trials Registry (ACTRN12617000707369). Between 13 January 2013 and 16 January 2017, 41 patients were randomly assigned to endoscopic dilatation (n = 21) or placebo (n = 20). The short-term response rate in the endoscopic dilatation group was 76% (n = 16), compared with 5% (n = 1) in the placebo group (P < 0.001). There were no serious adverse events. The finding of a mucosal tear postdilatation was associated strongly with clinical response (OR 13.4, 95% CI [2.4, 74.9], P = 0.003). Kaplan-Meier estimate of dysphagia relapse is 50% by 9.6 months (95% CI [6.0, 19.2]) from completion of dilatation. Endoscopic dilatation of the POJ is a safe and efficacious therapy for the treatment of long-term dysphagia in HNC survivors. Close follow-up and repeat dilatation are necessary given the high dysphagia relapse rate.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Transtornos de Deglutição / Deglutição / Dilatação / Neoplasias de Cabeça e Pescoço Tipo de estudo: Clinical_trials / Etiology_studies / Observational_studies / Risk_factors_studies Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Transtornos de Deglutição / Deglutição / Dilatação / Neoplasias de Cabeça e Pescoço Tipo de estudo: Clinical_trials / Etiology_studies / Observational_studies / Risk_factors_studies Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2019 Tipo de documento: Article